US Patent Issued to The Catholic University of America on Oct. 27 for "Bacteriophage-based, needle and adjuvant-free, mucosal COVID-19 vaccine" (District Of Columbia Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,773,449, issued on Oct. 27, was assigned to The Catholic University of America (Washington).

"Bacteriophage-based, needle and adjuvant-free, mucosal COVID-19 vaccine" was invented by Venigalla B. Rao (Washington) and Jingen Zhu (Washington).

According to the abstract* released by the U.S. Patent & Trademark Office: "A bacteriophage T4-based, multivalent/multicomponent, needle and adjuvant-free, mucosal vaccine by engineering spike trimers on capsid exterior and nucleocapsid protein in the interior is disclosed herein. Intranasal administration of this T4-COVID vaccine induces higher virus neutralization antibody titers against multiple variants, balanced Th1/Th2 antibody and cytokine...